Sections

Sections Protein C Deficiency
Overview
Presentation
DDx
Workup
Treatment
- Medical Care
- Consultations
- Diet
- Activity
- Prevention
- Show All
Medication
Questions & Answers
Media Gallery
References

Presentation

History

Individuals with hereditary protein C deficiency can present with venous thromboembolism (VTE), warfarin-induced skin necrosis in adults, and neonatal purpura fulminans in newborns who are homozygous or compound heterozygous for protein C mutation. Obtaining a detailed history that focuses on personal history—including previous history of thrombosis and any abnormal laboratory results—family history, and obstetric history is paramount.

Venous Thromboembolism

The most common sites of VTE are the deep veins of the leg (DVT), mesenteric veins, and pulmonary veins. Other sites, including cerebral veins, portal veins, superficial veins, or other unusual sites are also reported.^{[61, 62]}

In patients who present with VTE or warfarin-induced skin necrosis, family history is the best predictor for congenital thrombophilia. The initial episode of VTE in individuals with protein C deficiency is apparently spontaneous in approximately two-thirds of cases, and the other third usually have typical risk factors such as pregnancy, oral contraceptives, surgery, or trauma. Among patients with a positive family history, the risk is as high as 75% in those with severely affected families and closer to 30% in members of other families.^[62]

Warfarin-induced skin necrosis

Wafarin-induced skin necrosis (WISN) typically develops in the first few days of warfarin therapy, often in patients given large loading doses of 10 mg or more per day. If the patient is on warfarin and heparin, the lesions may appear upon discontinuation of the heparin. If a product containing protein C is not rapidly administered, the affected cutaneous area typically becomes edematous, develops central purpura, and eventually becomes necrotic.

WISN is not pathognomonic for protein C deficiency. It has been described in individuals with other inherited thrombophilias (factor V Leiden mutation, protein S deficiency) and transient reduction of protein C levels.^{[40, 41]}

Neonatal purpura fulminans

Purpura fulminans is a rare life-threatening condition in newborns characterized by disseminated intravascular coagulation (DIC), extensive venous and arterial thrombosis, and hemorrhagic skin necrosis. Laboratory testing reveals evidence of DIC and extremely low protein levels of less than 1% of normal.

Physical Examination

Patients with symptomatic hereditary protein C deficiency may present with VTE or WISN. Homozygotes and compound heterozygotes frequently present with neonatal purpura fulminans during the first hours of life.

Venous thromboembolism

Findings of acute VTE on physical examination are discussed in topics elsewhere (see Further Reading). Deep venous thrombosis of the lower extremity may be complicated by postthrombotic syndrome, a chronic condition associated with swelling, pain, discoloration, and venous insufficiency of the lower extremity.

Warfarin-induced skin necrosis

The skin lesions of WISN occur on the extremities, torso, breasts, and penis. They begin as erythematous macules and, if appropriate therapy is not initiated promptly, evolve to become purpuric and necrotic bullae. See image below.

A patient with warfarin-induced skin necrosis.

View Media Gallery

Neonatal purpura fulminans

Affected neonates present with diffuse ecchymoses that, like the lesions of WISN, progress to form necrotic bullae if appropriate therapy is not rapidly instituted. See image below.

A patient with neonatal purpura fulminans.

View Media Gallery

Differential Diagnoses

Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood. 2008 Jul 1. 112(1):19-27. [Medline]. [Full Text].
Pepler L, Wu C, Dwivedi DJ, Wu C, Kim PY, Liaw PC. The impact of the endothelial protein C receptor on thrombin generation and clot lysis. Thromb Res. 2017 Apr. 152:30-37. [Medline].
Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. N Engl J Med. 1986 May 15. 314(20):1298-304. [Medline].
Walker FJ. Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem. 1980 Jun 25. 255(12):5521-4. [Medline]. [Full Text].
Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007 Apr 15. 109(8):3161-72. [Medline]. [Full Text].
Danese S, Vetrano S, Zhang L, Poplis VA, Castellino FJ. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood. 2010 Feb 11. 115(6):1121-30. [Medline]. [Full Text].
D'Ursi P, Marino F, Caprera A, Milanesi L, Faioni EM, Rovida E. ProCMD: a database and 3D web resource for protein C mutants. BMC Bioinformatics. 2007 Mar 8. 8 Suppl 1:S11. [Medline]. [Full Text].
Bovill EG, Bauer KA, Dickerman JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood. 1989 Feb 15. 73(3):712-7. [Medline]. [Full Text].
Limperger V, Klostermeier UC, Kenet G, Holzhauer S, Alhenc Gelas M, Finckh U, et al. Clinical and laboratory characteristics of children with venous thromboembolism and protein C-deficiency: an observational Israeli-German cohort study. Br J Haematol. 2014 Nov. 167 (3):385-93. [Medline].
Horellou MH, Conard J, Bertina RM, Samama M. Congenital protein C deficiency and thrombotic disease in nine French families. Br Med J (Clin Res Ed). 1984 Nov 10. 289(6454):1285-7. [Medline]. [Full Text].
Reitsma PH, Poort SR, Allaart CF, Briet E, Bertina RM. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. Blood. 1991 Aug 15. 78(4):890-4. [Medline]. [Full Text].
Mustafa S, Mannhalter C, Rintelen C,et al. Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden. Blood Coagul Fibrinolysis. 1998 Jan. 9(1):85-9. [Medline].
Inoue H, Terachi SI, Uchiumi T, Sato T. The clinical presentation and genotype of protein C deficiency with double mutations of the protein C gene. Pediatric Blood Cancer. 2017 July 24. vol 64:[Medline]. [Full Text].
Saray A, Mesihovic R, Vanis N, Amila M. Protein C Deficiency in Chronic Hepatitis C: Correlation With Histological Extent of Liver Fibrosis. Clin Appl Thromb Hemost. 2017 Jan. 23 (1):72-77. [Medline].
Molino D, De Lucia D, Marotta R, Perna A, Lombardi C, Cirillo M, et al. In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. Kidney Int. 2005 Sep. 68 (3):1223-9. [Medline]. [Full Text].
Mitchell CA, Rowell JA, Hau L, Young JP, Salem HH. A fatal thrombotic disorder associated with an acquired inhibitor of protein C. N Engl J Med. 1987 Dec 24. 317(26):1638-42. [Medline].
Gordon B, Haire W, Ruby E, et al. Prolonged deficiency of protein C following hematopoietic stem cell transplantation. Bone Marrow Transplant. 1996 Mar. 17(3):415-9. [Medline].
Gerson WT, Dickerman JD, Bovill EG, Golden E. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics. 1993 Feb. 91(2):418-22. [Medline].
Schlegel N. Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost. 1997. 23 (3):271-80. [Medline].
MacCallum PK, Cooper JA, Martin J, Howarth DJ, Meade TW, Miller GJ. Associations of protein C and protein S with serum lipid concentrations. British Journal of Haematology. 2001 dec 25. 102:609-615. [Medline]. [Full Text].
Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 1995 Jan. 73(1):87-93. [Medline].
Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med. 1987 Oct 15. 317(16):991-6. [Medline].
Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost. 1997 Mar. 77(3):444-51. [Medline].
Gu Y, Shen W, Zhang L, Zhang J, Ying C. Deficiency of antithrombin and protein C gene in 202 Chinese venous thromboembolism patients. Int J Lab Hematol. 2014 Apr. 36 (2):151-5. [Medline].
Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990 Nov 29. 323(22):1512-6. [Medline].
Patel RK, Ford E, Thumpston J, Arya R. Risk factors for venous thrombosis in the black population. Thromb Haemost. 2003 Nov. 90(5):835-8. [Medline].
Sakata T, Kario K, Katayama Y, et al. Studies on congenital protein C deficiency in Japanese: prevalence, genetic analysis, and relevance to the onset of arterial occlusive diseases. Semin Thromb Hemost. 2000. 26(1):11-6. [Medline].
Nardi M, Karpatkin M. Prothrombin and protein C in early childhood: normal adult levels are not achieved until the fourth year of life. J Pediatr. 1986 Nov. 109(5):843-5. [Medline].
van Teunenbroek A, Peters M, Sturk A, Borm JJ, Breederveld C. Protein C activity and antigen levels in childhood. Eur J Pediatr. 1990 Aug. 149(11):774-8. [Medline].
Lensen RP, Rosendaal FR, Koster T, et al. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood. 1996 Dec 1. 88(11):4205-8. [Medline]. [Full Text].
Melissari E, Kakkar VV. Congenital severe protein C deficiency in adults. Br J Haematol. 1989 Jun. 72(2):222-8. [Medline].
Ichiyama M, Ohga S, Ochiai M, Fukushima K, Ishimura M, Torio M, et al. Fetal hydrocephalus and neonatal stroke as the first presentation of protein C deficiency. Brain Dev. 2016 Feb. 38 (2):253-6. [Medline].
Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998 Oct 1. 92(7):2353-8. [Medline]. [Full Text].
Koster T, Rosendaal FR, Briet E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995 May 15. 85(10):2756-61. [Medline]. [Full Text].
Pabinger I, Schneider B, for the Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Arterioscler Thromb Vasc Biol. 1996 Jun. 16(6):742-8. [Medline]. [Full Text].
de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP, for the Cerebral Venous Sinus Thrombosis Study Group. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. BMJ. 1998 Feb 21. 316(7131):589-92. [Medline]. [Full Text].
Momoi A, Komura Y, Kumon I, et al. Mesenteric venous thrombosis in hereditary protein C deficiency with the mutation at Arg169 (CGG-TGG). Intern Med. 2003 Jan. 42(1):110-6. [Medline]. [Full Text].
Wysokinska EM, Wysokinski WE, Brown RD, et al. Thrombophilia differences in cerebral venous sinus and lower extremity deep venous thrombosis. Neurology. 2008 Feb 19. 70(8):627-33. [Medline].
Sun L, Li X, Li Q, Wang L, Li J, Shu C. Multiple arterial and venous thromboembolism in a male patient with hereditary protein C deficiency: A case report. Medicine (Baltimore). 2021 Apr 16. 100 (15):e25575. [Medline]. [Full Text].
McGehee WG, Klotz TA, Epstein DJ, Rapaport SI. Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med. 1984 Jul. 101(1):59-60. [Medline].
Pourdeyhimi N, Bullard Z. Warfarin-induced skin necrosis. Hosp Pharm. 2014 Dec. 49 (11):1044-8. [Medline]. [Full Text].
Faraci PA, Deterling RA Jr, Stein AM, Rheinlander HF, Cleveland RJ. Warfarin induced necrosis of the skin. Surg Gynecol Obstet. 1978 May. 146(5):695-700. [Medline].
Broekmans AW, Teepe RG, van der Meer FJ, Briet E, Bertina RM. Protein C (PC) and coumarin-induced skin necrosis. Thromb Res. 1986. 41(suppl 1):137.
Parsi K, Younger I, Gallo J. Warfarin-induced skin necrosis associated with acquired protein C deficiency. Australas J Dermatol. 2003 Feb. 44 (1):57-61. [Medline].
Sallah S, Abdallah JM, Gagnon GA. Recurrent warfarin-induced skin necrosis in kindreds with protein S deficiency. Haemostasis. 1998 Jan-Feb. 28(1):25-30. [Medline].
Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet. 1996 Oct 5. 348(9032):913-6. [Medline].
Vossen CY, Preston FE, Conard J, et al. Hereditary thrombophilia and fetal loss: a prospective follow-up study. J Thromb Haemost. 2004 Apr. 2(4):592-6. [Medline]. [Full Text].
Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003 Mar 15. 361(9361):901-8. [Medline].
Kohler J, Kasper J, Witt I, von Reutern GM. Ischemic stroke due to protein C deficiency. Stroke. 1990 Jul. 21(7):1077-80. [Medline]. [Full Text].
Camerlingo M, Finazzi G, Casto L, et al. Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology. 1991 Sep. 41(9):1371-3. [Medline].
Peterman MA, Roberts WC. Syndrome of protein C deficiency and anterior wall acute myocardial infarction at a young age from a single coronary occlusion with otherwise normal coronary arteries. Am J Cardiol. 2003 Sep 15. 92(6):768-70. [Medline].
Douay X, Lucas C, Caron C, Goudemand J, Leys D. Antithrombin, protein C and protein S levels in 127 consecutive young adults with ischemic stroke. Acta Neurol Scand. 1998 Aug. 98(2):124-7. [Medline].
Munts AG, van Genderen PJ, Dippel DW, van Kooten F, Koudstaal PJ. Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol. 1998 Jan. 245(1):21-5. [Medline].
Boekholdt SM, Kramer MH. Arterial thrombosis and the role of thrombophilia. Semin Thromb Hemost. 2007 Sep. 33(6):588-96. [Medline].
Folsom AR, Ohira T, Yamagishi K, Cushman M. Low protein C and incidence of ischemic stroke and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. J Thromb Haemost. 2009 Nov. 7(11):1774-8. [Medline]. [Full Text].
Kenet G, Lütkhoff LK, Albisetti M, Bernard T, Bonduel M, Brandao L, et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation. 2010 Apr 27. 121(16):1838-47. [Medline].
Komai H, Shindo S, Sato M, Ogino H. Reduced Protein C Activity Might be Associated With Progression of Peripheral Arterial Disease. Angiology. 2014 Aug 12. [Medline].
Seligsohn U, Berger A, Abend M, et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med. 1984 Mar 1. 310(9):559-62. [Medline].
Peters C, Casella JF, Marlar RA, Montgomery RR, Zinkham WH. Homozygous protein C deficiency: observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy. Pediatrics. 1988 Feb. 81(2):272-6. [Medline].
Marciniak E, Wilson HD, Marlar RA. Neonatal purpura fulminans: a genetic disorder related to the absence of protein C in blood. Blood. 1985 Jan. 65(1):15-20. [Medline]. [Full Text].
Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. New England Journal of Medicine. 1983 Aug 11. 309:340-344. [Medline]. [Full Text].
Martinelli I1, Mannucci PM, De Stefano V, Taioli E, Rossi V, Crosti F, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998 Oct 1. 92:2353-2358. [Medline]. [Full Text].
Yilmaz S, Gunaydin S. Inherited risk factors in low-risk venous thromboembolism in patients under 45 years. Interact Cardiovasc Thorac Surg. 2014 Oct 17. [Medline].
Michiels JJ, Hamulyak K. Laboratory diagnosis of hereditary thrombophilia. Semin Thromb Hemost. 1998. 24(4):309-20. [Medline].
Dolan G, Neal K, Cooper P, Brown P, Preston FE. Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol. 1994 Apr. 86(4):798-803. [Medline].
Martinoli JL, Stocker K. Fast functional protein C assay using Protac, a novel protein C activator. Thromb Res. 1986 Aug 1. 43(3):253-64. [Medline].
Jones DW, Mackie IJ, Winter M, Gallimore M, Machin SJ. Detection of protein C deficiency during oral anticoagulant therapy--use of the protein C:factor VII ratio. Blood Coagul Fibrinolysis. 1991 Jun. 2(3):407-11. [Medline].
Linn YC, Tien SL. Detection of protein C or protein S deficiency in patients on warfarin therapy--a study of nine patients. Ann Acad Med Singapore. 1994 Sep. 23(5):775-80. [Medline].
Emmanuel J. Favaloro and Giuseppe Lippi. Interference of direct oral anticoagulants in haemostasis assays: high potential for diagnostic false positives and false negatives. Blood Transfusion. 2017 Nov. 15:491-494. [Medline]. [Full Text].
Milleret C, Epiard C, Douchin S, Pernod G, Debillon T. Early antithrombotic treatment with warfarin oral suspension in severe neonatal protein C deficiency. Arch Pediatr. 2017 Apr. 24 (4):363-366. [Medline].
Schramm W, Spannagl M, Bauer KA, et al. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol. 1993 Jun. 129(6):753-6. [Medline].
Watanabe K, Arakawa Y, Yanagi M, Isobe K, Mori M, Koh K. Management of severe congenital protein C deficiency with a direct oral anticoagulant, edoxaban: A case report. Pediatr Blood Cancer. 2019 Jun. 66 (6):e27686. [Medline].
Kamada M, Kenzaka T. Successful treatment of warfarin-induced skin necrosis using oral rivaroxaban: A case report. World J Clin Cases. 2019 Dec 26. 7 (24):4285-4291. [Medline]. [Full Text].
Menon N, Sarode R, Zia A. Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis. Blood Adv. 2018 Jan 23. 2 (2):142-145. [Medline]. [Full Text].
Minford A, Behnisch W, Brons P, David M, Gomez Gomez N, Hertfelder HJ, et al. Subcutaneous protein C concentrate in the management of severe protein C deficiency--experience from 12 centres. Br J Haematol. 2014 Feb. 164 (3):414-21. [Medline].
Conard J, Bauer KA, Gruber A, et al. Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. Blood. 1993 Aug 15. 82(4):1159-64. [Medline]. [Full Text].
Dreyfus M, Ladouzi A, Chambost H, et al, for the PROTEXEL Study Group. Treatment of inherited protein C deficiency by replacement therapy with the French purified plasma-derived protein C concentrate (PROTEXEL). Vox Sang. 2007 Oct. 93(3):233-40. [Medline].
Hartman KR, Manco-Johnson M, Rawlings JS, Bower DJ, Marlar RA. Homozygous protein C deficiency: early treatment with warfarin. Am J Pediatr Hematol Oncol. 1989 Winter. 11(4):395-401. [Medline].
Minford AM, Parapia LA, Stainforth C, Lee D. Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate. Br J Haematol. 1996 Apr. 93(1):215-6. [Medline].
Lee MJ, Kim KM, Kim JS, Kim YJ, Lee YJ, Ghim TT. Long-term survival of a child with homozygous protein C deficiency successfully treated with living donor liver transplantation. Pediatr Transplant. 2009 Mar. 13 (2):251-4. [Medline].
Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med. 2009 Mar 3. 150(5):293-300. [Medline].
Klein TE, Altman RB, Eriksson N, et al, for the International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009 Feb 19. 360(8):753-64. [Medline]. [Full Text].

Media Gallery

The protein C pathway. APC = activated protein C; PC = protein C; S= protein S; T = thrombin; TM = thrombomodulin; Va = factor Va; VIII = factor VIIIa.
A patient with warfarin-induced skin necrosis.
A patient with neonatal purpura fulminans.

of 3

Author

Shamudheen Rafiyath, MD Medical Oncologist, Hematologist, Arizona Blood and Cancer Specialists

Shamudheen Rafiyath, MD is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Perumal Thiagarajan, MD Professor, Department of Pathology and Medicine, Baylor College of Medicine; Director, Transfusion Medicine and Hematology Laboratory, Michael E DeBakey Veterans Affairs Medical Center

Perumal Thiagarajan, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Society for Biochemistry and Molecular Biology, American Society for Clinical Investigation, American Society of Hematology, Association of American Physicians, Royal College of Physicians

Disclosure: Nothing to disclose.

Additional Contributors

Eleanor S Pollak, MD Associate Director of Special Coagulation, Associate Professor, Department of Pathology and Laboratory Medicine, Section of Hematology and Coagulation, University of Pennsylvania

Eleanor S Pollak, MD is a member of the following medical societies: American Society of Hematology, College of American Pathologists, National Multiple Sclerosis Society

Disclosure: Nothing to disclose.

David Aboulafia, MD Medical Director, Bailey-Boushay House, Clinical Professor, Department of Medicine, Division of Hematology, Attending Physician, Section of Hematology/Oncology, Virginia Mason Clinic; Investigator, Virginia Mason Community Clinic Oncology Program/SWOG

David Aboulafia, MD is a member of the following medical societies: American College of Physicians, American Medical Association, AMDA - The Society for Post-Acute and Long-Term Care Medicine, American Society of Hematology, Infectious Diseases Society of America, Phi Beta Kappa

Disclosure: Nothing to disclose.

Adam Cuker, MD, MS Assistant Professor of Medicine, Assistant Professor of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania

Adam Cuker, MD, MS is a member of the following medical societies: American College of Physicians, American Society of Hematology, Anticoagulation Forum, Hemostasis and Thrombosis Research Society, International Society on Thrombosis and Haemostasis

Disclosure: Received research grant from: Alexion; Bayer; Bioverativ; Novo Nordisk; Pfizer; Shire; Spark; Syntimmune<br/>Received income in an amount equal to or greater than $250 from: Genzyme; Kedrion; Synergy.

Sections Protein C Deficiency
Overview
Presentation
DDx
Workup
Treatment
- Medical Care
- Consultations
- Diet
- Activity
- Prevention
- Show All
Medication
Questions & Answers
Media Gallery
References

Protein C Deficiency Clinical Presentation

History

Physical Examination

Venous thromboembolism

Warfarin-induced skin necrosis

Neonatal purpura fulminans

References

Tables

Contributor Information and Disclosures

What would you like to print?